SEC Tracker
Get the app
DSGN · XBRL financial data

Design Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (DSGN's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue————year only00*0*0*00*0*
Research and development11,012*9,80110,51611,87612,157*15,37715,73814,58913,425*14,37916,38816,926
General and administrative4,109*4,5994,5274,3704,537*5,0415,8314,7224,744*5,3275,7895,304
Total operating expenses15,121*14,40015,04316,24616,694*20,41821,56919,31118,169*19,70622,17722,230
Operating income (loss)(15,121)*(14,400)(15,043)(16,246)(16,694)*(20,418)(21,569)(19,311)(18,169)*(19,706)(22,177)(22,230)
Interest incomeyear only3,2953,2503,2073,043*2,7032,4862,3142,172*2,0702,0121,942
Other income (expense)3,279*3,2953,2503,207————————
Income tax expense (benefit)————year only———year only———
Net income (loss)(11,842)*(11,105)(11,793)(13,039)(13,651)*(17,715)(19,083)(16,997)(15,997)*(17,636)(20,165)(20,288)
Earnings per share, basic USD per share(0.21)*(0.20)(0.21)(0.23)(0.24)*(0.31)(0.34)(0.30)(0.27)*(0.29)(0.32)(0.32)
Earnings per share, diluted USD per share(0.21)*(0.20)(0.21)(0.23)(0.24)*(0.31)(0.34)(0.30)(0.27)*(0.29)(0.32)(0.32)
Weighted average shares, basic thousands of shares56,091*56,48956,55656,62156,682*56,75856,85956,95158,735*61,43462,50563,036
Weighted average shares, diluted thousands of shares56,091*56,48956,55656,62156,682*56,75856,85956,95158,735*61,43462,50563,036

Balance sheet

CSV

Fiscal quarters (DSGN's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents21,20029,39745,69930,32822,56313,66719,70315,08816,85612,77012,90715,252
Marketable securities260,598241,289215,317223,746222,914216,007196,573190,882202,989210,053194,489193,356
Prepaid and other current assets2,7863,2003,8263,1682,5633,9703,5183,0593,9394,2264,6175,355
Total current assets284,584273,886264,842257,242248,040233,644219,794209,029223,784227,049212,013213,963
Property and equipment, net1,6911,7181,7281,5591,4101,3771,2581,104981824694573
Right-of-use asset2,9382,7622,5832,4012,2162,0271,8341,6371,4382,5692,4222,272
Total assets289,643278,793269,582261,629252,093237,475222,886211,770226,203230,442215,129216,808
Accounts payable1,9401,3721,2971,4702,1863,1801,0131,9132,3122,2763,1412,078
Accrued liabilities7,6825,7225,0975,9626,2765,0567,7349,26010,7437,9148,09910,675
Total current liabilities9,6227,0946,3947,4328,4628,2368,74711,17313,05510,19011,24012,753
Lease liability, non-current2,3342,1421,9461,7441,5341,3201,1028776452,1982,0311,859
Total liabilities11,9569,2368,3409,1769,9969,5569,84912,05013,70012,38813,27114,612
Accumulated deficit(177,626)(188,731)(200,524)(213,563)(227,214)(244,929)(264,012)(281,009)(297,006)(314,642)(334,807)(355,095)
Total stockholders' equity277,687269,557261,242252,453242,097227,919213,037199,720212,503218,054201,858202,196
Total liabilities and equity289,643278,793269,582261,629252,093237,475222,886211,770226,203230,442215,129216,808
Common shares outstanding (cover page) thousands of shares56,49456,49556,62156,62156,76356,76956,94856,96461,67262,45762,58264,036

Cash flows

CSV

Fiscal quarters (DSGN's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(11,842)*(11,105)(11,793)(13,039)(13,651)*(17,715)(19,083)(16,997)(15,997)*(17,636)(20,165)(20,288)
Stock-based compensation2,724*3,1843,299*3,118*3,471*3,5393,985*3,590*3,435*3,9243,867*4,051*
Net cash from operating activities(12,798)*(12,439)(11,260)*(9,546)*(9,860)*(16,789)(14,441)*(11,162)*(11,966)*(16,431)(15,524)*(15,378)*
Purchases of property and equipment27*195161*(16)*0*7287*0*34*021*15*
Net cash from investing activities5,555*20,61627,333*(5,826)*1,832*7,87020,116*6,510*(11,583)*(7,589)15,056*189*
Proceeds from issuing common stock————year only00*0*24,847*19,9070*17,257*
Net cash from financing activities501*20229*1*263*23361*37*25,317*19,934605*17,534*
Net change in cash(6,742)*8,19716,302*(15,371)*(7,765)*(8,896)6,036*(4,615)*1,768*(4,086)137*2,345*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Design Therapeutics15,252not reported(15,378)*64.0M13.2 quarters 10-QSep 30, 2026
Alector75,472162,866(24,154)*148.9M3.8 quarters 10-QSep 30, 2026
Protalix BioTherapeutics27,42019,896(10,400)*80.6M2.6 quarters 10-QJun 30, 2026
Fate Therapeutics43,9420(27,800)121.6M5.1 quarters 10-QSep 30, 2026
Caribou Biosciences26,0571,607(22,518)*108.0M3.9 quarters 10-QSep 30, 2026
Protara Therapeutics17,076not reported(15,389)*59.1M10.5 quarters 10-QJun 30, 2026
TuHURA Biosciences996not reported(8,634)*63.7M0.1 quarters 10-QJun 30, 2026
Enanta Pharmaceuticals33,41914,359(9,972)*29.1M21.2 quarters 10-QJun 30, 2026
Galectin Therapeutics13,269not reported(2,439)*100.8M5.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.